 |
市場調査レポート
商品コード
1533623
コンパニオン診断の市場規模、シェア、成長分析：製品・サービス別、技術別、適応症別、地域別 - 産業予測、2024年～2031年Companion Diagnostics Market Size, Share, Growth Analysis, By Product and Services (Assays, Kits, Reagents, Software & Services), By Technology (PCR, ISH), By Indication (Cardiovascular, Oncology), By Region - Industry Forecast 2024-2031 |
||||||
| コンパニオン診断の市場規模、シェア、成長分析：製品・サービス別、技術別、適応症別、地域別 - 産業予測、2024年～2031年 |
|
出版日: 2024年08月02日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界のコンパニオン診断の市場規模は、2022年に66億2,000万米ドルとなり、2023年の73億7,000万米ドルから、2031年までには174億8,000万米ドルに成長し、予測期間（2024年～2031年）のCAGRは11.4%で成長する見通しです。
コンパニオン診断は、特にがんの診断や治療において、特定の生物学的製剤や医薬品を安全かつ効果的に使用するために不可欠です。これらの検査は、特定のバイオマーカーを同定することにより、個々の患者に対する治療戦略をカスタマイズする上で極めて重要です。例えば、Foundation MedicineのFOUNDATIONONE CDxは、300以上のがん関連遺伝子の徹底的な解析を提供する注目すべきコンパニオン診断です。この詳細な遺伝子解析は、広範な固形がんの標的治療や個別化がん治療の選択に役立つ重要な洞察を提供します。コンパニオン診断は、医療従事者が十分な情報を得た上で治療法を決定できるようにすることで、個々の患者のニーズに合わせたがん治療の有効性と安全性の両方を大幅に向上させます。
目次
イントロダクション
- 調査の目的
- 定義
- 市場範囲
調査手法
- 情報調達
- 二次・一次情報源
- 市場規模予測
- 市場の前提条件と制限
エグゼクティブサマリー
- 市場概要見通し
- 供給需要動向分析
- セグメント別機会分析
市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- ポーターの分析
主要な市場の考察
- 技術分析
- 価格分析
- バリューチェーン分析
- サプライチェーン分析
- 貿易分析
- 市場のエコシステム
- スタートアップ分析
- 特許分析
- 顧客と購買基準の分析
- 規制情勢
- イノベーションマトリクス
- 主要な投資分析
- 主要な成功要因
- 市場魅力度指数
- 競合の程度
コンパニオン診断市場：製品・サービス別
- 市場概要
- アッセイ、キット、試薬
- 機器とシステム
- ソフトウェア・サービス
コンパニオン診断市場：技術別
- 市場概要
- ポリメラーゼ連鎖反応
- インサイチューハイブリダイゼーション
- 次世代シーケンシング
- 免疫組織化学
- その他の技術
コンパニオン診断市場：適応症別
- 市場概要
- がん
- 肺がん
- 乳がん
- 血液がん
- 大腸がん
- その他のがん
- 神経疾患
- 心血管疾患
- 感染症
- その他の適応症
コンパニオン診断市場：サンプルタイプ別
- 市場概要
- 組織サンプル
- 血液サンプル
- その他のサンプルタイプ
コンパニオン診断市場：エンドユーザー別
- 市場概要
- 製薬・バイオテクノロジー企業
- リファレンスラボ
- ヘルスケア・医薬品
- その他のエンドユーザー
コンパニオン診断市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2023年）
- 主要な市場企業が採用した戦略
- 市場における最近の活動
- 主要企業の市場シェア（2023年）
主要企業プロファイル
- IDEXX Laboratories, Inc.（US）
- Zoetis Inc.（US）
- Heska Corporation（US）
- Thermo Fisher Scientific, Inc.（US）
- Virbac SA（France）
- IDVet（France）
- NEOGEN Corporation（US）
- bioMerieux SA（France）
- Randox Laboratories Ltd.（UK）
- AniCell Biotech（US）
- Bionote Inc.（South Korea）
- Bio-Rad Laboratories, Inc.（US）
- Antech Diagnostics（US）
- Eurofins Scientific SE（Luxembourg）
- Animalytix LLC（US）
- Advanced Animal Diagnostics（US）
- Roche Diagnostics（Switzerland）
- Agilent Technologies, Inc.（US）
- Myriad Genetics, Inc.（US）
- Illumina, Inc.（US）
- Qiagen N.V.（Netherlands）
Global Companion Diagnostic Market size was valued at USD 6.62 billion in 2022 and is poised to grow from USD 7.37 billion in 2023 to USD 17.48 billion by 2031, growing at a CAGR of 11.4% in the forecast period (2024-2031).
Companion diagnostics are essential for the safe and effective use of specific biological products or medications, especially in cancer diagnosis and treatment. These tests are pivotal in customizing therapeutic strategies for individual patients by identifying particular biomarkers. For instance, Foundation Medicine's FOUNDATIONONE CDx is a notable companion diagnostic that offers a thorough analysis of over 300 cancer-related genes. This detailed genetic analysis provides critical insights that help in selecting targeted and personalized cancer treatments for a wide range of solid tumors. By enabling healthcare professionals to make well-informed decisions about treatment options, companion diagnostics significantly improve both the efficacy and safety of cancer therapies tailored to individual patient needs.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Companion Diagnostic market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Companion Diagnostic Market Segmental Analysis
The Companion Diagnostic Market is segmented based on product and services, Technology, indication and region. Based on product and services, the market is segmented into assay kits and reagents, and software and services. Based on industry, the market is segmented into polymerase chain reaction, immunohistochemistry, in situ hybridization, and next-generation sequencing, among others. Based on indication, the market is segmented into oncology, neurology, and others. Based on region, the market is segmented into North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Drivers of the Global Companion Diagnostic Market
Recent years have seen a significant rise in cancer cases, leading to increased demand for effective Companion Diagnostic (CDx) assays. This growing prevalence highlights the importance of genomic testing, which provides a detailed understanding of tumors' genetic profiles. Genomic testing helps characterize the genetic makeup of tumors and offers precise guidance to healthcare professionals on appropriate treatment strategies. Consequently, the rise in cancer cases is driving up sales of CDx products. These diagnostics are crucial for personalizing treatment approaches, ensuring that patients receive targeted therapies based on their tumors' specific genetic features, and ultimately improving the effectiveness of cancer care.
Restraints in the Global Companion Diagnostic Market
Despite the increasing acceptance of companion diagnostic tests, a significant challenge remains due to the lack of a standardized method for setting reimbursement rates. Currently, these rates are determined on a case-by-case basis, leading to inconsistencies in the reimbursement process. For instance, our analysis reveals that in Germany, there is a notable variance in reimbursement structures between inpatient and outpatient care settings. In the inpatient system, diagnostics are generally covered under diagnosis-related groups, which provides a standardized approach within this context.
Market Trends of the Global Companion Diagnostic Market
Clinicians use Next-Generation Sequencing (NGS) to analyze a broad array of genes related to cancer development, utilizing surgically excised tumor samples from patients. NGS is distinguished by its ability to produce extensive genetic data quickly, making it a crucial tool in oncology. Ongoing technological advancements continue to improve the accuracy and effectiveness of this sequencing technique. According to a publication by the Centers for Disease Control and Prevention (CDC), NGS has evolved from being primarily a research tool to becoming a central element in clinical applications over the past five years. This transition highlights NGS's growing importance in understanding the genetic complexities of cancers, which enhances the precision and effectiveness of diagnostic and treatment strategies in clinical practice.
Table of Contents
Introduction
- Objectives of the Study
- Definitions
- Market Scope
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Market Overview Outlook
- Supply Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Value Chain Analysis
- Supply Chain Analysis
- Trade Analysis
- Ecosystem of the Market
- Start-up Analysis
- Patent Analysis
- Customer & Buying Criteria Analysis
- Regulatory Landscape
- Innovation Matrix
- Top Investment Analysis
- Key Success Factor
- Market Attractive Index
- Degree of Competition
Companion Diagnostic Market by Product & Service
- Market Overview
- Assays, Kits, and Reagents
- Instruments & Systems
- Software & Services
Companion Diagnostic Market by Technology
- Market Overview
- Polymerase Chain Reaction
- In Situ Hybridization
- Next-Generation Sequencing
- Immunohistochemistry
- Other Technologies
Companion Diagnostic Market by Indication
- Market Overview
- Cancer
- Lung Cancer
- Breast Cancer
- Blood Cancer
- Colorectal Cancer
- Other Cancer
- Neurological Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Other Indications
Companion Diagnostic Market by sample Types
- Market Overview
- Tissue Samples
- Blood Samples
- Other Sample types
Companion Diagnostic Market by End-User
- Market Overview
- Pharmaceutical & Biotechnology Companies
- Reference Laboratories
- Healthcare and Pharmaceutical
- Other End Users
Companion Diagnostic Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2023
- Strategies Adopted by Key Market Players
- Recent Activities in the Market
- Key Companies Market Share (%), 2023
Key Company Profiles
- IDEXX Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zoetis Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Heska Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Virbac SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IDVet (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- NEOGEN Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Randox Laboratories Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AniCell Biotech (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bionote Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Antech Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific SE (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Animalytix LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Advanced Animal Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Diagnostics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad Genetics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
